Tesamorelin is a synthetic peptide that helps the body naturally increase the production and release of growth hormone (GH). It is designed to mimic the action of growth hormone-releasing hormone (GHRH), which is a natural hormone produced in the brain that signals the pituitary gland to release GH. Tesamorelin is best known for its effect on reducing visceral adipose tissue (VAT), which is the deep abdominal fat that accumulates around internal organs. This type of fat is strongly associated with metabolic problems and HIV-associated lipodystrophy, a disorder of fat distribution that occurs during antiretroviral therapy.
Tesamorelin works by binding to GHRH receptors in the pituitary gland. This stimulates the body to release its own growth hormone in natural pulses, which then increases levels of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone associated with metabolism, tissue repair, maintaining muscle mass, and cell growth. Unlike direct growth hormone injections, tesamorelin does not replace GH from outside. Instead, it stimulates the body's natural growth hormone system.
Most studies on tesamorelin have focused on people living with HIV who develop excess abdominal fat during antiretroviral therapy. Clinical trials have repeatedly shown that tesamorelin can significantly reduce visceral fat, waist circumference and fat in the trunk, whilst generally preserving subcutaneous fat—that is, fat located beneath the skin—as well as fat in the arms and legs. In placebo-controlled trials lasting between 6 and 12 months, a reduction in visceral fat of approximately 10–18% was frequently observed. Researchers also noted improvements in body image and certain markers of metabolic health. At the same time, studies showed that after discontinuing tesamorelin, visceral fat gradually returned, suggesting that maintaining the effects may require continued therapy.
Tesamorelin has also been studied for its effects on fatty liver disease and metabolic health. In individuals with HIV-associated NAFLD, studies have demonstrated a reduction in the amount of fat deposited in the liver, along with improvements in metabolic markers related to the organ's function. Importantly, these effects were observed without significant worsening of blood sugar control. Researchers have also analysed the potential impact of tesamorelin on inflammation, fat metabolism, adipose tissue quality, healthy ageing, and brain function, due to its interaction with growth hormone and IGF-1 pathways associated with regeneration and metabolism.
Tesamorelin is considered a peptide as it is composed of amino acids arranged in a manner that mimics the body's natural GHRH. It is a modified and more stable version of natural GHRH, engineered to be more resistant to breakdown by enzymes in the body. This allows tesamorelin to remain active for longer and stimulate growth hormone release more effectively than natural GHRH, while still maintaining a more natural hormone secretion pattern.
Research also suggests that tesamorelin may improve body composition by reducing visceral fat while increasing lean body mass. Several clinical trials and scientific reviews have demonstrated reductions in waist circumference, trunk fat, and liver fat, along with increases in muscle mass and IGF-1 levels. These changes were typically achieved without severe side effects or major hormonal imbalances, which distinguishes tesamorelin from direct growth hormone therapy.
Although tesamorelin is primarily associated with HIV-related lipodystrophy, scientific interest has also expanded to other areas such as obesity-related metabolic disorders, fatty liver disease, healthy ageing, cognitive function, and adipose tissue biology. Researchers are particularly interested in the impact of GHRH analogues on visceral adipose tissue, mitochondrial function, inflammation, metabolism, and tissue regeneration mechanisms.
Disclaimer
The information about tesamorelin is for educational and scientific purposes only. Tesamorelin is a prescription peptide approved for specific medical uses, and research into its broader effects is ongoing. The studies, mechanisms, and findings described here are based on published scientific data and should not be considered medical advice, diagnosis, or treatment recommendations. Individuals considering hormone therapies or peptide-based interventions should consult with a qualified healthcare professional.
Jak działa Tesamorelin?
Tesamorelin works by mimicking the effects of the body's natural growth hormone-releasing hormone (GHRH), which is responsible for signalling the pituitary gland to release growth hormone (GH). When administered, tesamorelin binds to GHRH receptors on pituitary gland cells called somatotrophs. This causes the body's own GH to be released in natural pulses. As GH levels rise, the liver begins to produce more insulin-like growth factor-1 (IGF-1), which is responsible for many of the metabolic effects and body composition changes associated with tesamorelin.
The most important feature of tesamorelin's mechanism of action is that it enhances the body's natural growth hormone system rather than directly replacing growth hormone. This is significant because it preserves the natural hormonal feedback mechanism. Unlike direct GH injections, tesamorelin maintains the pulsatile secretion of growth hormone, meaning GH is released in rhythmic bursts that mimic natural physiology.
Metabolically, tesamorelin helps break down stored fat, particularly visceral fat located deep within the abdominal cavity. Growth hormone activates enzymes involved in lipolysis, which is the process of breaking down triglycerides stored in fat cells. Visceral fat is particularly susceptible to growth hormone because it contains many receptors that respond to GH and exhibits high metabolic activity. For this reason, tesamorelin primarily acts on deep abdominal fat while often preserving subcutaneous fat. Clinical studies have consistently demonstrated reductions in visceral fat, waist circumference, and trunk fat during tesamorelin therapy.
Another important aspect of tesamorelin's action is an increase in IGF-1 levels. This hormone is mainly produced in the liver after stimulation by growth hormone and supports muscle mass maintenance, tissue regeneration, protein synthesis, and metabolism. Higher IGF-1 levels are associated with an increase in lean body mass, improved regenerative processes, and enhanced cellular repair. Some studies also suggest that IGF-1 may support brain health, mitochondrial function, anti-inflammatory signalling, and neuronal cell protection, which is why tesamorelin has garnered interest in ageing and cognitive function research.
Tesamorelin may also improve liver health and fat metabolism. In studies on HIV-related fatty liver disease, tesamorelin reduced the amount of fat accumulating in the liver. Researchers believe this may be due to several mechanisms, including increased fat burning, reduced production of new fat in the liver, improved distribution of fat in the body, and limited transport of fatty acids from visceral fat to the liver.
Another important effect concerns inflammation and the quality of adipose tissue. Excess visceral fat is strongly associated with chronic low-grade inflammation, insulin resistance, and metabolic disorders. By reducing visceral fat, tesamorelin may indirectly improve inflammatory and metabolic markers. In some studies, improvements in triglyceride levels, adiponectin, and other metabolic indicators have been observed during therapy.
Tesamorelin has also been studied for its potential effects on brain function, as growth hormone and IGF-1 interact with many neurological processes. IGF-1 can cross the blood-brain barrier and is involved in the creation of new neurons, the survival of nerve cells, improved communication between neurons, and the reduction of oxidative stress. Researchers have analysed whether reducing abdominal fat and increasing IGF-1 could improve cognitive function in people with HIV-associated neurocognitive disorders. While some studies have shown an increase in IGF-1 levels and a reduction in waist circumference, improvements in cognitive function have generally been modest and not always statistically significant.
From a drug design perspective, tesamorelin was created as a stabilised version of GHRH. Natural GHRH breaks down very rapidly in the body, which limits its use. Tesamorelin incorporates structural changes that increase its resistance to enzymatic breakdown, making it remain active for longer and more effectively stimulate growth hormone release when administered subcutaneously.
Generally speaking, tesamorelin acts as a targeted peptide that enhances the body's natural growth hormone system. Its effects include growth hormone signalling, IGF-1 production, visceral fat metabolism, liver fat regulation, and tissue regeneration pathways. This combination of actions explains why tesamorelin has been extensively studied in the context of visceral fat reduction, HIV-related lipodystrophy, fatty liver disease, metabolic disorders, and other issues related to abnormal fat distribution.
Disclaimer
This explanation of tesamorelin's mechanism of action is for educational and scientific purposes only. While clinical and preclinical studies have analysed tesamorelin's impact on growth hormone signalling, metabolism, liver health, and body composition, research into its long-term safety and broader effects is ongoing. This content does not constitute medical advice and should not substitute consultation with a licensed healthcare professional.
References
- Falutz, J., Potvin, D., Mamputu, J.-C., Assaad, H., Zoltowska, M., Michaud, S.-E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone–releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomised placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. https://doi.org/10.1097/QAI.0b013e3181cbdaff
- Ellis, R. J., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R. K., Lee, D., & Sattler, F. S. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. The Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S. et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: A randomised, double-blind, multicentre trial. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
- Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., & Aberg, J. A. (2022). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
- Badran, A. S., Helal, A., Shata, K. S., & Ayesh, H. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomised controlled trials. Obesity Research & Clinical Practice, 20(1), 2–12. https://doi.org/10.1016/j.orcp.2026.01.002
- Falutz, J., Potvin, D., Mamputu, J.-C., Assaad, H., Zoltowska, M., Michaud, S.-E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone–releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomised placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. https://doi.org/10.1097/QAI.0b013e3181cbdaff
- Ellis, R. J., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R. K., Lee, D., & Sattler, F. S. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. The Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S. et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: A randomised, double-blind, multicentre trial. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
- Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., & Aberg, J. A. (2022). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
- Badran, A. S., Helal, A., Shata, K. S., & Ayesh, H. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomised controlled trials. Obesity Research & Clinical Practice, 20(1), 2–12. https://doi.org/10.1016/j.orcp.2026.01.002